Terns Pharmaceuticals Inc
(STU:430)
€
5.6
0.05 (0.9%)
Market Cap: 470.26 Mil
Enterprise Value: 113.82 Mil
PE Ratio: 0
PB Ratio: 1.34
GF Score: 39/100 Terns Pharmaceuticals Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 09, 2023 / 03:10PM GMT
Release Date Price:
€9.15
(+1.10%)
Paul Jeng
Guggenheim Partners - Analyst
All right. Good morning and welcome to this next session of the Guggenheim Oncology Conference. My name is Paul Jeng. I'm a member of the biotech research team at Guggenheim. And our next presenting company is Terns Pharmaceuticals. And I'm very pleased to welcome with us from the team, Mark Vignola, the CFO; and Erin Quirk, President and Head of R&D. Welcome.
Erin Quirk
Terns Pharmaceuticals, Inc. - President, Head of Research & Development
Thank you.
Mark Vignola
Terns Pharmaceuticals, Inc. - CFO
Thanks for having us.
Questions & Answers
Paul Jeng;Erin Quirk
Guggenheim Partners - Analyst;Terns Pharmaceuticals, Inc. -
All right. So let's start with an overview question. So Terns has a pretty unique approach focused on validated targets across oncology as well as metabolic diseases. So maybe you could start by providing just a brief intro to the company and the platform.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot